Eli Lilly and Company (NYSE: LLY), a United States-based pharmaceutical company, announced on Tuesday that it is planning to invest an additional USD450m and create around 100 new jobs to expand its manufacturing capacity at the firm's Research Triangle Park facility in North Carolina.

The expansion includes additional parenteral filling, device assembly and packaging capacity in order to support an increased demand for the company's incretin products that treat diabetes.

When the facility is completely operational in 2027, this phase of the project is likely to create around 100 new jobs, mainly manufacturing personnel, who will use advanced technology to develop incretin treatments and medical devices.